Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes

Author:

Rothermundt Christian1,Bailey Alexandra2,Cerbone Linda3,Eisen Tim4,Escudier Bernard5,Gillessen Silke1,Grünwald Viktor6,Larkin James7,McDermott David2,Oldenburg Jan8,Porta Camillo9,Rini Brian10,Schmidinger Manuela11,Sternberg Cora3,Putora Paul M.1213

Affiliation:

1. Division of Haematology and Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland;

2. Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;

3. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy;

4. Department of Oncology, Cambridge University Hospitals National Health Service Foundation, Cambridge, United Kingdom;

5. Gustave Roussy, Villejuif, France;

6. Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany;

7. The Royal Marsden Hospital, London, United Kingdom;

8. Department of Oncology, Akershus University Hospital and Medical Faculty of University of Oslo, Oslo, Norway;

9. Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy;

10. Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio, USA;

11. Abteilung für Onkologie, Allgemeines Krankenhaus-Universitätskliniken, Wien, Austria;

12. Faculty of Medicine, University of Oslo, Oslo, Norway;

13. Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland

Abstract

Abstract Background. With the advent of targeted therapies, many treatment options in the first-line setting of metastatic clear cell renal cell carcinoma (mccRCC) have emerged. Guidelines and randomized trial reports usually do not elucidate the decision criteria for the different treatment options. In order to extract the decision criteria for the optimal therapy for patients, we performed an analysis of treatment algorithms from experts in the field. Materials and Methods. Treatment algorithms for the treatment of mccRCC from experts of 11 institutions were obtained, and decision trees were deduced. Treatment options were identified and a list of unified decision criteria determined. The final decision trees were analyzed with a methodology based on diagnostic nodes, which allows for an automated cross-comparison of decision trees. The most common treatment recommendations were determined, and areas of discordance were identified. Results. The analysis revealed heterogeneity in most clinical scenarios. The recommendations selected for first-line treatment of mccRCC included sunitinib, pazopanib, temsirolimus, interferon-α combined with bevacizumab, high-dose interleukin-2, sorafenib, axitinib, everolimus, and best supportive care. The criteria relevant for treatment decisions were performance status, Memorial Sloan Kettering Cancer Center risk group, only or mainly lung metastases, cardiac insufficiency, hepatic insufficiency, age, and “zugzwang” (composite of multiple, related criteria). Conclusion. In the present study, we used diagnostic nodes to compare treatment algorithms in the first-line treatment of mccRCC. The results illustrate the heterogeneity of the decision criteria and treatment strategies for mccRCC and how available data are interpreted and implemented differently among experts. Implications for Practice: The data provided in the present report should not be considered to serve as treatment recommendations for the management of treatment-naïve patients with multiple metastases from metastatic clear cell renal cell carcinoma outside a clinical trial; however, the data highlight the different treatment options and the criteria used to select them. The diversity in decision making and how results from phase III trials can be interpreted and implemented differently in daily practice are demonstrated.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3